{"id":610557,"date":"2026-08-31T21:42:20","date_gmt":"2026-08-31T21:42:20","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/610557\/"},"modified":"2026-08-31T21:42:20","modified_gmt":"2026-08-31T21:42:20","slug":"has-novo-nordisk-finally-found-the-catalyst-that-could-flip-the-script-on-eli-lilly","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/610557\/","title":{"rendered":"Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?"},"content":{"rendered":"

Novo Nordisk (NVO<\/a> -0.61%) started the GLP-1 weight-loss revolution that is sweeping the world. Its Wegovy\/Ozempic shot was so popular that the company couldn’t keep up with demand. That proved to be a major problem for the company, particularly after competitor Eli Lilly (LLY<\/a> -1.52%) introduced its own GLP-1 weight-loss drug, Zepbound\/Mounjaro, which enabled greater weight loss. <\/p>\n

But Novo Nordisk has been fighting back. Right now, that’s all about its Wegovy pill. But a new partnership with Vivani Medical (VANI<\/a> -2.11%) could flip the script on the entire GLP-1 industry. <\/p>\n

\"A<\/p>\n

Image source: Getty Images.<\/p>\n

Novo Nordisk is working to get back on top<\/p>\n

The healthcare industry<\/a> is highly innovative and highly competitive. It isn’t surprising at all that Novo Nordisk’s early success in the GLP-1 weight-loss niche didn’t last. But the fact that Eli Lilly introduced a more desirable GLP-1 product should not be taken as an indication that it has a permanent lead. <\/p>\n

One of the big problems with early GLP-1 weight-loss drugs<\/a> is the delivery method. Shots are not something that most people like to take, let alone give to themselves on a weekly basis. Which is why both Eli Lilly and Novo Nordisk were working on daily pills. Novo Nordisk was, again, first to market with a pill version of Wegovy. The uptake of this version of the drug has been strong, as you might expect. <\/p>\n

\"Eli<\/p>\n

Today’s Change<\/p>\n

(-1.52%) $-17.88<\/p>\n

Current Price<\/p>\n

$1,156.73<\/p>\n

Key Data Points<\/p>\n

Market Cap<\/p>\n

$1.1TMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.<\/p>\n

Day’s Range<\/p>\n

$1147.00 – $1171.45<\/p>\n

52wk Range<\/p>\n

$712.05 – $1292.65<\/p>\n

Volume<\/p>\n

3.1M<\/p>\n

Avg Vol<\/p>\n

2.9M<\/p>\n

Gross Margin<\/p>\n

83.40%<\/p>\n

Dividend Yield<\/p>\n

0.57%<\/p>\n

Eli Lilly has since introduced its own GLP-1 pill. However, that pill delivers a different GLP-1 drug, known as Foundayo. That means Eli Lilly can’t lean as heavily on its success with Zepbound\/Mounjaro when marketing Foundayo. It has to introduce an entirely new drug, which is a much more difficult process. Novo Nordisk is in an advantaged position, for now.<\/p>\n

Novo Nordisk leans into convenience <\/p>\n

The difference between a shot and a pill is pretty big. While a daily pill may require more frequent dosing, it is likely to be seen as much more convenient than a weekly shot. But Novo Nordisk isn’t done yet. It inked a deal with Vivani Medical to explore an implant that will automatically administer Novo Nordisk’s Wegovy.<\/p>\n

\"Novo<\/p>\n

Today’s Change<\/p>\n

(-0.61%) $-0.28<\/p>\n

Current Price<\/p>\n

$45.33<\/p>\n

Key Data Points<\/p>\n

Market Cap<\/p>\n

$153BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.<\/p>\n

Day’s Range<\/p>\n

$44.95 – $45.61<\/p>\n

52wk Range<\/p>\n

$35.12 – $64.16<\/p>\n

Volume<\/p>\n

7.6M<\/p>\n

Avg Vol<\/p>\n

12.3M<\/p>\n

Gross Margin<\/p>\n

80.65%<\/p>\n

Dividend Yield<\/p>\n

3.94%<\/p>\n

Research on this delivery method is still in its early stages, but it could mean patients only need to manage their GLP-1 drugs once or twice a year. That would take convenience to the next level and could totally change the dynamics of the GLP-1 race. At this point, it doesn’t appear that Eli Lilly is working on anything similar.<\/p>\n

It is too early to suggest that Novo Nordisk has found the tool it needs to regain the GLP-1 lead. But in the highly innovative pharmaceutical sector<\/a>, it is clearly working hard to differentiate its weight-loss offerings. The more choices patients have with Wegovy, the more ways Novo Nordisk has to catch up to Eli Lilly. <\/p>\n

Eli Lilly isn’t sitting still; it’s moving in a different direction<\/p>\n

For its part, Eli Lilly has been using its GLP-1 success to expand its business into new treatment areas. That may sound like a mistake as Novo Nordisk leans into the hot GLP-1 niche, but it really isn’t. In the second quarter of 2026, GLP-1 drugs accounted for roughly two-thirds of Eli Lilly’s revenue. From a strategic standpoint, focusing on diversification is a good plan. <\/p>\n

Still, Novo Nordisk’s continued innovation in the GLP-1 space could give it a chance to regain the lead. And that’s something that investors shouldn’t ignore, noting that Eli Lilly’s price-to-earnings ratio is 40x compared to Novo Nordisk’s 11.5x. The underdog here looks relatively cheap, but it also isn’t out of the fight yet.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (NVO -0.61%) started the GLP-1 weight-loss revolution that is sweeping the world. Its Wegovy\/Ozempic shot was…\n","protected":false},"author":2,"featured_media":610558,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[103,397,396,61,60],"class_list":["post-610557","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-health-care","tag-healthcare","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/610557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=610557"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/610557\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/610558"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=610557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=610557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=610557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}